Published: Feb 17, 2026
Written by Klarity Editorial Team
Published: Feb 17, 2026

For the millions of women who suffer from Premenstrual Dysphoric Disorder (PMDD), access to effective treatment can be life-changing. Yaz (drospirenone/ethinyl estradiol) is an FDA-approved treatment for PMDD, but many patients wonder: can I legally get this medication through telehealth? With evolving healthcare regulations and telehealth expansion, the answer is a resounding yes—but it’s important to understand the legal landscape that makes this possible.
This comprehensive guide breaks down the current regulations around prescribing Yaz via telehealth in 2025, addressing common misconceptions and providing clarity for patients seeking convenient care options for PMDD.
Yaz is an FDA-approved oral contraceptive that contains drospirenone (3mg) and ethinyl estradiol (0.02mg). Beyond its contraceptive use, Yaz is specifically approved for the treatment of PMDD. Crucially, Yaz is classified as a non-controlled prescription medication (also called a ‘legend drug’). This classification is the foundation of its telehealth accessibility.
One of the most common misconceptions patients have is confusing prescription medications with controlled substances. Here’s the important distinction:
Controlled Substances (Schedules I-V): Medications with potential for abuse or dependence that are regulated by the DEA under the Controlled Substances Act. These include medications like Adderall, Xanax, and opioid painkillers.
Non-Controlled Prescription Medications: Prescription medications that do not have significant potential for abuse. These include antibiotics, birth control pills like Yaz, blood pressure medications, and many others.
Yaz falls into the non-controlled category, which means it isn’t subject to the stricter telehealth prescribing rules that apply to controlled substances.
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is frequently misunderstood. This federal law requires an in-person examination before a controlled substance can be prescribed via telehealth, with certain exceptions. However, this law does not apply to non-controlled medications like Yaz.
This means there is no federal law requiring an in-person visit before Yaz can be prescribed via telehealth—a key point that even some healthcare providers may misunderstand.
For non-controlled medications like Yaz, federal regulations establish a permanent foundation for telehealth prescribing. Unlike the complex and changing landscape for controlled substances (where temporary COVID-era flexibilities are extended through December 31, 2025), the rules for prescribing non-controlled medications via telehealth are stable and permissive.
While federal law provides the foundation, state regulations add specific requirements. Here’s how telehealth prescribing of Yaz works in key states:
California has some of the most progressive telehealth laws in the nation. Recent legislation (AB 1503, passed in October 2025) reinforces the ‘standard of care’ model, further supporting telehealth access to medications like Yaz. California explicitly allows:
California’s nurse practitioners can work either independently (if classified as ‘104 NPs’) or in group settings with physicians (as ‘103 NPs’), both of which can facilitate telehealth access to Yaz.
Texas has modernized its telemedicine regulations, with the Texas Medical Board implementing simplified rules in January 2025. For Yaz prescriptions:
One Texas-specific consideration: Nurse practitioners must have a Prescriptive Authority Agreement (PAA) with a physician. This is a behind-the-scenes collaboration requirement that doesn’t typically affect the patient experience but is part of the regulatory framework.
Florida explicitly permits audio-only telehealth for non-controlled substances like Yaz under HB 267 (effective since July 2023). This is particularly helpful for patients with limited internet access. Florida offers:
Florida’s Advanced Practice Registered Nurses (APRNs) can either practice autonomously (if registered for autonomous practice) or under a protocol with a physician, both of which can support telehealth prescribing.
New York has robust telehealth infrastructure and regulations that support prescribing Yaz without in-person visits. Key features include:
The New York Nurse Practitioner Modernization Act provisions were extended through July 1, 2026, continuing to support independent practice for experienced NPs.
For PMDD diagnosis and treatment via telehealth, providers must still meet the standard of care, which includes:
Telehealth platforms like Klarity Health have developed comprehensive assessment protocols that meet or exceed these requirements. Through secure video consultations and digital health questionnaires, providers can gather the necessary information to make appropriate clinical decisions about PMDD treatment.
Most patients with PMDD symptoms are eligible for telehealth evaluation and potential Yaz treatment. However, certain situations may require in-person evaluation:
At Klarity Health, providers conduct thorough screenings to determine if telehealth is appropriate for each individual patient, ensuring safe and effective care.
False. There is no federal or state requirement for an in-person visit before prescribing non-controlled medications like Yaz via telehealth. The standard of care can be met through a comprehensive virtual assessment.
False. As of 2025, all 50 states permit telehealth prescribing of non-controlled medications like Yaz, though specific requirements vary by state. The broad adoption of telehealth has led to standardization of these practices nationwide.
Not necessarily true. Many states have telehealth parity laws requiring insurance to cover telehealth services similarly to in-person care. Additionally, platforms like Klarity Health work with many insurance plans and offer transparent cash pricing options for those who prefer to pay directly.
Find the right provider for your needs — select your state to find expert care near you.